Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Chongqing Precision Biotech Co., Ltd clinical trials
The registry lists 51 studies whose lead sponsor is Chongqing Precision Biotech Co., Ltd. 37 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.
Keep track of what changes. Save the Chongqing Precision Biotech Co., Ltd studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 50
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chongqing Precision Biotech Co., Ltd.
- Chongqing Precision Biotech Co., Ltd51 studiesSame company
Something wrong?
Focus areas
Conditions Chongqing Precision Biotech Co., Ltd leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Phase 2
- Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCNRecruitingNCT06690827Phase 1
- In Vivo PICX CAR-T Therapy for R/R Multiple MyelomaRecruitingNCT07715630Phase 1
- Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07637929
- PIC1 Injection Therapy for Relapsed/Refractory B-NHLRecruitingNCT07456371Phase 1
- Study of CD19 CAR-T Therapy for Refractory SLERecruitingNCT07403097Phase 1
- Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLERecruitingNCT07318259Phase 1
- Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLERecruitingNCT07331467Phase 1
- Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLERecruitingNCT06892145Phase 1
- In VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesRecruitingNCT07239323Phase 1
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid TumorsRecruitingNCT07179692Phase 1
- Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic DiseasesRecruitingNCT07184450Phase 1
- Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung CancerRecruitingNCT06945523Phase 1
- Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung CancerRecruitingNCT06992583Phase 1
- Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic MalignanciesRecruitingNCT06909474Phase 1
- Anti-CEA CAR-T for Advanced CEA-Positive Lung CarcinomaRecruitingNCT06903117Phase 1
- A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04776330Phase 1/2
- BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04271644Phase 1/2
- A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALLRecruitingNCT04781634Phase 1/2
- A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung CancerRecruitingNCT06768151Phase 1
- Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)RecruitingNCT06686524Phase 1
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALLNot yet recruitingNCT06641024Phase 1
- Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile DermatomyositisRecruitingNCT06569472Phase 1
- CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid TumorsRecruitingNCT06006390Phase 1/2
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerRecruitingNCT06215950Phase 1
- Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin LymphomaRecruitingNCT05420493Phase 1
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaRecruitingNCT06180174Phase 1
- Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06126406Phase 1
- Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsRecruitingNCT06010862Phase 1
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingNCT06010875Phase 1
- Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune DiseaseRecruitingNCT06056921Phase 1
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsRecruitingNCT06043466Phase 1
- A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-TRecruitingNCT05468190Phase 1
- Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal CancerRecruitingNCT05420519Phase 1
- A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingNCT05420545Phase 1
- Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT04272125Phase 1/2
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid TumorsSuspendedNCT07181720Phase 1
- Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmCompletedNCT06006403Phase 1/2
- Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05538195Phase 1/2
- Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ CancerWithdrawnNCT04348643Phase 1/2
- Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05415475Phase 1
- Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT04861480Phase 1
- CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04265963Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04782193Phase 1/2
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04272151Phase 1/2
- Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsCompletedNCT04888468Phase 1